Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

ol pharma tech, llc drs pharmacy - bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), pramoxine hydrochloride (unii: 88ayb867l5) (pramoxine - unii:068x84e056) - first aid to help prevent infection in minor • cuts • scrapes • burns - first aid antibiotic - external analgesic do not use • if you are allergic to any of the ingredients • in the eyes • over large areas of the body • longer than 1 week unless directed by a doctor stop use and ask a doctor if • the condition persists or gets worse • a rash or other allergic reaction develops

Sjedinjene Američke Države - engleski - NLM (National Library of Medicine)

fresenius kabi usa, llc - zinc sulfate (unii: 89ds0h96tb) (zinc cation - unii:13s1s8sf37) - zinc sulfate injection is indicated in adult and pediatric patients as a source of zinc for parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. zinc sulfate injection is contraindicated in patients with known hypersensitivity to zinc [see warnings and precautions (5.6) ] risk summary administration of the approved recommended dose of zinc sulfate injection in parenteral nutrition is not expected to cause major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal reproduction studies have not been conducted with intravenous zinc sulfate. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. clinical considerations disea

Australija - engleski - Department of Health (Therapeutic Goods Administration)

care pharmaceuticals pty ltd - zinc oxide -

Kanada - engleski - Health Canada

taro pharmaceuticals inc - polymyxin b (polymyxin b sulfate); bacitracin zinc; gramicidin - ointment - 10000unit; 500unit; 0.25mg - polymyxin b (polymyxin b sulfate) 10000unit; bacitracin zinc 500unit; gramicidin 0.25mg - antibiotics

Kanada - engleski - Health Canada

cellchem pharmaceuticals inc. - polymyxin b sulfate; bacitracin zinc; gramicidin - ointment - 10000unit; 500unit; 0.25mg - polymyxin b sulfate 10000unit; bacitracin zinc 500unit; gramicidin 0.25mg - antibiotics

Kanada - engleski - Health Canada

taro pharmaceuticals inc - polymyxin b sulfate; gramicidin; lidocaine; bacitracin zinc - ointment - 10000unit; 0.25mg; 50mg; 500unit - polymyxin b sulfate 10000unit; gramicidin 0.25mg; lidocaine 50mg; bacitracin zinc 500unit - antibiotics

Australija - engleski - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - mecobalamin, quantity: 5 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - cobalamin deficiency may exist that is unable to be corrected by oral intake and in these cases parenteral administration may be preferable. oral administration of vitamin b12 may be insufficient in pernicious anaemia, malabsorption disorders, gastrectomy and gastrointestinal pathologies. specific indications may include: 1. pernicious anaemia as a result of in situ b12 deficiency. in pernicious anaemia co-methylcobalamin is disproportionately reduced in relation to other cobalamins. 2. as an adjunct to the treatment of peripheral neuropathies and diabetic polyneuropathy.

Filipini - engleski - FDA (Food And Drug Administration)

d.b. manix international, inc.; distributor: metz pharmaceuticals, inc. - retinol palmitate (vit. a) , ascorbic acid (vit. c) , dl-alpha tocopheryl acetate (vit. e) , zinc - softgel capsule - 5000 iu/ 500 mg/ 100 iu/ 25 mg

Australija - engleski - Department of Health (Therapeutic Goods Administration)

bio-rad laboratories pty ltd - ct922 - microbiological culture media ivds - prepared microbiological culture media, including agar containing selecting agents, antimicrobials, chromogenic agents or chemical indicators for colony differentiation.

Novi Zeland - engleski - Medsafe (Medicines Safety Authority)

a. menarini new zealand pty ltd - rosuvastatin calcium 10.4mg equivalent to rosuvastatin 10mg;   - film coated tablet - 10 mg - active: rosuvastatin calcium 10.4mg equivalent to rosuvastatin 10mg   excipient: calcium phosphate crospovidone hypromellose iron oxide red lactose monohydrate   magnesium stearate microcrystalline cellulose purified water titanium dioxide triacetin - crestor should be used as an adjunct to diet when the response to diet and exercise is inadequate. prevention of major cardiovascular events in adult patients without documented history of cardiovascular or cerebrovascular events, but with at least two conventional risk factors for cardiovascular disease, (see clinical efficacy) crestor is indicated to: reduce the risk of nonfatal myocardial infarction reduce the risk of nonfatal stroke reduce the risk of coronary artery revascularisation